Haleon plc (LON:HLN) Given Average Recommendation of “Moderate Buy” by Analysts

Haleon plc (LON:HLN) has been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is GBX 398.67.

HLN has been the topic of several research reports. Berenberg Bank restated a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research report on Thursday, April 30th. Jefferies Financial Group lowered their price objective on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research report on Thursday, April 30th.

Insider Buying and Selling at Haleon

In other news, insider Brian McNamara sold 63,012 shares of the firm’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total transaction of £231,884.16. Company insiders own 0.01% of the company’s stock.

Haleon Stock Performance

Haleon stock opened at GBX 334 on Friday. The firm’s fifty day moving average price is GBX 340.56 and its 200-day moving average price is GBX 364.79. The company has a debt-to-equity ratio of 52.26, a quick ratio of 0.93 and a current ratio of 0.92. The stock has a market cap of £29.55 billion, a P/E ratio of 18.05, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25. Haleon has a fifty-two week low of GBX 317.80 and a fifty-two week high of GBX 416.10.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.